evipedia.ai
← Back

Combining Topical Ascorbic Acid & DMSO to Treat Skin Cancer

Evidence Review created on 10/19/2026 using AI4L / Opus 5.5

Also known as: Topical Vitamin C & DMSO, Ascorbic Acid in DMSO, Ascorbic Acid, L-Ascorbic Acid, Vitamin C, Ascorbate, Dimethyl Sulfoxide, DMSO, Methyl Sulfoxide, Rimso-50

Motivation

Basal cell and squamous cell skin cancers are the most frequently diagnosed cancers in fair-skinned people, and those who stay active outdoors across a long, health-focused life often face several of them. This review covers a home-applied solution of concentrated vitamin C (ascorbic acid) dissolved in dimethyl sulfoxide, a solvent that passes readily through skin. At very high local concentrations, vitamin C stops acting as an antioxidant and instead generates hydrogen peroxide, which some cancer cells handle poorly.

Interest comes from two directions. Laboratory work on high-dose vitamin C revived a decades-old debate about its place in cancer care, and dimethyl sulfoxide has a long history as a skin-penetrating carrier with a devoted following among proponents of alternative therapies. A few small clinical studies have since tested the mixture on early skin cancers, attracting attention as a possible low-cost option that avoids surgery.

This review examines what the clinical and laboratory evidence shows about the combination’s ability to clear skin cancers, its side effects and interactions, how it has been applied in studies, and how that evidence compares with surgery and standard prescription creams.

Benefits - Risks - Protocol - Conclusion

Five in-depth sources on applying concentrated ascorbic acid with dimethyl sulfoxide (DMSO, a solvent that carries dissolved substances through skin) to basal cell carcinoma (BCC, the most common, slow-growing skin cancer) and related skin cancers, and on the mechanisms behind it.

No relevant content from Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine or Lifespan.io was found; none of these platforms has covered this combination, whose evidence consists of a few small dermatology studies.

Grokipedia

No Grokipedia article on topical ascorbic acid combined with DMSO was found.

Examine

No Examine article on topical ascorbic acid combined with DMSO exists; Examine has no DMSO page and returned no results for topical vitamin C in skin cancer.

ConsumerLab

Systematic Reviews

Three systematic reviews cover topical vitamin C in skin cancer, the adverse reactions of DMSO, and the established basal cell carcinoma treatments the combination would replace.

Mechanism of Action

At ordinary levels, ascorbic acid (vitamin C) is an antioxidant. At very high tissue concentrations it forms hydrogen peroxide outside cells, which killed several cancer cell lines in the laboratory while sparing normal cells (Chen et al., 2005).

  • Ascorbic acid properties: enters skin only below pH 3.5; in pig skin, uptake peaked at 20% concentration and tissue levels fell with a half-life of about 4 days (Pinnell et al., 2001). It is oxidized, largely without enzymes, to dehydroascorbic acid and cleared by the kidneys.
  • DMSO properties: loosens the outer skin barrier and carries dissolved compounds through it (Marren, 2011). It distributes through body tissues and is converted (responsible enzymes not well characterized) to dimethyl sulfone and dimethyl sulfide (exhaled, causing garlic-like odor) (Rimso-50 label). Elimination slows at high levels, giving no fixed half-life; 44% of an intravenous dose leaves unchanged in urine within a day (Egorin et al., 1998).
  • Why combined: sequential action. DMSO, a penetration-enhancing solvent (Capriotti & Capriotti, 2012), carries ascorbate below the skin surface, where ascorbate supplies the peroxide-generating action.
  • Consequences of co-administration: the agents share no known metabolic pathway; the intended effect is deeper ascorbate penetration. Tumor ascorbate levels remain unmeasured.
  • Competing view: DMSO scavenges hydroxyl radicals (highly reactive oxygen fragments) (Babbs & Griffin, 1989), which could blunt part of ascorbate’s oxidative damage; since killing depended on hydrogen peroxide, the concern is limited but untested.

Historical Context & Evolution

Ascorbic acid was isolated in the 1930s as the vitamin that prevents scurvy and later became a staple of cosmetic serums. DMSO, a by-product of paper-pulp processing, drew medical interest in the 1960s for crossing skin; lens changes were reported in dogs given high oral doses (Rubin & Mattis, 1966), and its only approved human drug use today is bladder instillation for interstitial cystitis (a chronic bladder pain condition) (Rimso-50 label).

Vitamin C’s cancer history began with Cameron and Pauling, who reported that 100 terminal cancer patients given ascorbate survived over four times longer than 1,000 comparison patients (Cameron & Pauling, 1976). Two later placebo-controlled trials using oral doses found no benefit (Creagan et al., 1979; Moertel et al., 1985). Pharmacokinetic work (how the body absorbs and clears a substance) then showed that oral dosing cannot reach the blood levels that intravenous dosing produces, so those trials never tested the concentrations that kill cancer cells in the laboratory (Padayatty et al., 2004). Both positive and negative trials remain part of the record rather than a settled verdict.

Because skin cancers sit at the surface, researchers reasoned that topical application could deliver high concentrations. A Budapest team reported an aqueous ascorbic acid solution for BCC in 2016 (Holló et al., 2016), an Italian group described an SCC case in 2021 (Pernice et al., 2021), and an Idaho group combined ascorbic acid with DMSO in a randomized trial (Burke & Bailie, 2022). No independent group has yet repeated the combination trial.

Expected Benefits

Both clinical studies of the combination, a randomized trial in BCC and an uncontrolled preprint in SCC in situ (confined to the top skin layer), tested the two agents together; no study has compared the combination with ascorbic acid alone or DMSO alone.

High 🟩 🟩 🟩

No benefit reaches High: the only controlled human data on the combination come from one small randomized trial run by a single research group.

Medium 🟩 🟩

Biopsy-Confirmed Clearance of Low-Risk BCC and SCC In Situ

The only randomized trial of the combination found twice-daily 30% ascorbic acid in DMSO cleared nodular (raised) and superficial (flat) BCC more often than imiquimod at 8 weeks and non-inferior (not worse within a preset margin) at 12 weeks (Burke & Bailie, 2022). The trial was small (25 patients), excluded high-risk sites and subtypes, and was sponsored by the investigators’ own company. For SCC in situ, only an uncontrolled preprint from that group exists (Miller et al., 2025); aqueous ascorbic acid alone cleared one invasive case (Pernice et al., 2021).

Magnitude: BCC: 13 of 15 lesions (86.7%) cleared on biopsy versus 8 of 14 (57.1%) with imiquimod at 8 weeks, 29.6 percentage points more than imiquimod (p < 0.05, a result unlikely to be chance; no confidence interval, the range of plausible values, reported). SCC in situ: 15 of 27 lesions (56%) cleared on biopsy at 12 weeks (no control group).

Fewer Pigment Changes Than Imiquimod

Treated sites showed no lasting skin lightening, whereas imiquimod frequently left hypopigmentation (pale patches) at long-term follow-up (Burke & Bailie, 2022). The evidence tested the combination against an active comparator in the same single randomized trial; patient-rated cosmetic scales were not reported in the abstract. Avoiding excision also avoids a surgical scar, a common reason for choosing topical treatment.

Magnitude: Residual hypopigmentation at 30 months in 0% of ascorbate-treated patients versus 70% of imiquimod-treated patients, 70 percentage points fewer than imiquimod (no confidence interval reported).

Low 🟩

Speculative 🟨

Activity Against Melanoma

Vitamin C triggered death of melanoma cells in culture (Chen et al., 2019). No human study has applied the combination to melanoma; the basis is laboratory data only.

Faster Response Through DMSO Carriage

DMSO alone is a penetration-enhancing solvent (Capriotti & Capriotti, 2012) that could carry ascorbate deeper and speed regression versus aqueous formulas. No study compared ascorbic acid with and without DMSO; the basis is mechanistic only.

Benefit-Modifying Factors

  • Genetic polymorphisms: No inherited gene variant is known to change response. In laboratory tests, sensitivity to ascorbate varied widely between cancer cell lines (Chen et al., 2005), pointing to tumor properties rather than inherited ones.
  • Baseline biomarker levels: No blood marker predicts response. Blood vitamin C status is irrelevant because oral intake cannot approach the concentrations applied to the lesion (Padayatty et al., 2004).
  • Baseline lesion characteristics: Evidence covers nodular and superficial BCC averaging about 11–13 mm; infiltrative (growing in strands into deeper skin), morpheaform (scar-like, deeply spreading) and recurrent BCC were excluded (NCT04279535), so results do not extend to them.
  • Tumor type: Controlled evidence covers BCC only; for SCC there are an uncontrolled preprint on SCC in situ (Miller et al., 2025), a pilot without posted results (NCT05932511) and a single aqueous case (Pernice et al., 2021), so response in invasive SCC is unknown.
  • Lesion site: BCC on the nose, ears, eyelids, eyebrows or temples was excluded because tumors there spread beyond visible borders (NCT04279535).
  • Sex: Neither combination study reported results by sex. After DMSO-supported photodynamic therapy (PDT, light-activated cream treatment) for BCC, male sex predicted recurrence (Christensen et al., 2009), an indirect signal.
  • Pre-existing health conditions: Immunocompromised people and people with diabetes were excluded from the SCC pilot (NCT05932511), so no response data exist for them; poor surgical candidates are the group an Italian team expects to gain most (Pernice et al., 2021).
  • Age: The BCC trial enrolled adults aged 18–80 (NCT04279535); older adults whose health complicates surgery stand to gain most from a non-surgical route, though no age-specific results exist.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: the replicated human data on skin reactions and odor come from DMSO-alone studies at larger doses than a lesion application, and the combination’s own data come from one research group.

Medium 🟥 🟥

Local Skin Reactions at the Application Site

DMSO commonly causes burning, itching, redness and hives where applied, documented across 43 skin-application studies reviewed by Kollerup Madsen et al., 2018 and in a clinical review by Swanson, 1985. Reactions are dose-related and usually last minutes. Gap: these studies tested DMSO alone, mostly at larger doses than 0.2–0.3 mL on one lesion; the highly acidic ascorbic acid adds irritation potential. The combination trial reported fewer adverse effects than imiquimod, without rates in its abstract (Burke & Bailie, 2022).

Magnitude: With topical DMSO, burning or stinging and hives were each reported in 16% of users, redness in 9% and itching in 6%, as summarized by ConsumerLab from the Kollerup Madsen et al., 2018 review (no control group).

Garlic-Like Breath and Body Odor

DMSO is partly converted to dimethyl sulfide, which leaves through breath and skin as a garlic-like odor. Halitosis (bad breath) appeared in 29 studies in the review by Kollerup Madsen et al., 2018, and the manufacturer’s Rimso-50 label notes odor lasting up to 72 hours. Evidence is for DMSO alone; the combination studies did not report odor, and their 0.2–0.3 mL doses are far smaller than in most DMSO studies.

Magnitude: Reported in 29 studies; every participant was affected in five studies, and some studies recorded discontinuations for odor (no control group).

Incomplete Clearance and Delayed Definitive Treatment

Some lesions do not clear, and residual tumor can sit beneath healed-looking skin; repeat biopsies found persisting carcinoma in the BCC trial (Burke & Bailie, 2022). Without biopsy before and after, an unrecognized melanoma or aggressive SCC could grow during topical treatment. Evidence comes from one group’s trial of the combination; its abstract and registry record give no recurrence data for cleared lesions. A Cochrane review found that imiquimod, another topical option, recurs more often than surgery (Thomson et al., 2020).

Magnitude: 2 of 15 BCC lesions still contained tumor at 8 weeks versus 6 of 14 with imiquimod, 29.6 percentage points fewer than imiquimod (Burke & Bailie, 2022).

Low 🟥

Acute Allergic Reactions

DMSO releases histamine and has caused occasional allergic reactions with skin use (Rimso-50 label). Acute allergic reactions appeared in six studies, mostly intravenous (Kollerup Madsen et al., 2018). Evidence is for DMSO alone; combination studies reported none.

Magnitude: Acute allergic reactions in 6 of 109 studies, mostly after intravenous dosing; no rate for small skin doses is reported (no control group).

Headache, Nausea and Dizziness

Skin-applied DMSO enters the bloodstream and has caused headache, nausea and dizziness (Kollerup Madsen et al., 2018). Gap: those doses covered larger areas or other routes than 0.2–0.3 mL on one lesion; combination studies reported no systemic effects.

Magnitude: Nausea occurred in 2–14% of participants in most studies across routes, less often with skin application (no control group).

Speculative 🟨

Eye Lens Changes ⚠️ Conflicted

Animal-only signal: high oral DMSO doses altered lens focusing in dogs (Rubin & Mattis, 1966). Human eye examinations in the Kollerup Madsen et al., 2018 review found none. Net: no human signal at studied doses.

Absorption of Impurities From Industrial-Grade DMSO

Non-pharmaceutical DMSO may contain contaminants that DMSO itself carries through skin (ConsumerLab). No resulting human harm is documented; the basis is mechanistic.

Risk-Modifying Factors

  • Genetic polymorphisms: G6PD deficiency (inherited lack of an enzyme protecting red blood cells from oxidative damage) underlies most reported vitamin C hemolysis (red-blood-cell destruction) after gram-level oral or intravenous doses (Juneja et al., 2022); topically, the risk is theoretical.
  • Baseline biomarker levels: No blood test predicts skin irritation; a low G6PD activity result is the one laboratory finding that flags a higher, theoretical hemolysis risk.
  • Baseline skin reactivity: People with dermatographism (skin that welts when scratched) developed prominent welts after DMSO (Kollerup Madsen et al., 2018); a history of reactions to topical products signals higher irritation risk.
  • Sex: No sex differences in DMSO or ascorbic acid skin reactions have been reported; the combination trial enrolled similar numbers of women and men (NCT04279535).
  • Pre-existing health conditions: Eczema or broken skin increases absorption and irritation; immunosuppression raises the cost of a missed or incompletely treated SCC; pregnancy is a concern because high DMSO doses caused birth defects in some animal studies (Rimso-50 label).
  • Age: Thinner skin and reduced vision or dexterity increase spill onto healthy skin; the BCC trial enrolled adults up to 80 years (NCT04279535), but no age-specific safety data exist.

Key Interactions & Contraindications

Prescription drugs

  • Sulindac (a prescription anti-inflammatory) — Avoid: Severe, partly lasting peripheral neuropathy (nerve damage) followed topical 90% DMSO use in a man taking sulindac (Reinstein et al., 1982). Mitigation: no co-use; DMSO stopped at any numbness or weakness.
  • Topical corticosteroids (anti-inflammatory steroid creams: hydrocortisone, fluocinolone acetonide) — Caution: DMSO creates a steroid reservoir in human skin and increases absorption (Stoughton, 1965), raising the risk of skin thinning and systemic steroid effects. Mitigation: no steroid on the treated site.
  • Topical aminoglycoside antibiotics (a group of antibiotics that can damage hearing once absorbed: neomycin) — Avoid on treated skin: DMSO increased neomycin absorption enough to cause ototoxicity (hearing damage) (Herd et al., 1967). Mitigation: a non-aminoglycoside product if the site needs an antibiotic.
  • Other topical prescription drugs on the same site (imiquimod; 5-fluorouracil, a chemotherapy cream; tretinoin, a vitamin A cream) — Caution: DMSO may strengthen the effect of other medications used alongside it (Rimso-50 label), intensifying inflammation or systemic exposure. Mitigation: sequential rather than layered use.
  • Anticoagulants (blood thinners: warfarin, apixaban) — Monitor (theoretical): Laboratory data suggest DMSO can impair clotting (ConsumerLab), a possible increase in local bleeding; unlikely at lesion doses. Mitigation: observation of the site for bleeding or bruising.

Over-the-counter medications

  • Topical diclofenac gel — Caution: DMSO is used in a marketed solution to boost diclofenac absorption, with dry skin as the commonest adverse event (Simon et al., 2009); co-application raises local drug exposure and irritation. Mitigation: application to separate areas.
  • Benzoyl peroxide, glycolic acid or retinol products — Caution (theoretical): additive irritation and oxidation of ascorbic acid, which may reduce activity. Mitigation: pausing these products on the treated site during the course.
  • Oral pain relievers (acetaminophen, ibuprofen) — No interaction identified: no human data suggest a consequence at lesion doses.

Supplements

  • Oral vitamin C supplements — No interaction expected (theoretical): oral intake cannot raise tissue levels near those reached topically (Padayatty et al., 2004), so supplements neither add to nor reduce the local effect.
  • Methylsulfonylmethane (MSM, identical to DMSO’s metabolite dimethyl sulfone) — Monitor (theoretical): additive exposure to the same sulfur compound, with possible added odor. Mitigation: pausing MSM during the course.
  • Topical essential oils (tea tree, oregano) — Caution (theoretical): DMSO increases penetration of sensitizing compounds, raising the risk of allergic contact dermatitis (allergic skin rash). Mitigation: keeping oils off the treated area.
  • Corrosive herbal salves (black salve, bloodroot) — Avoid (theoretical): these pastes destroy tissue; DMSO could drive them deeper, causing deeper wounds and scarring. Mitigation: no combined use.

Other interventions

  • Sun exposure and tanning — Caution (theoretical): ultraviolet light keeps generating new lesions and may irritate treated skin. Mitigation: covering the treated site and sun protection outdoors.
  • Cryotherapy (freezing treatment), laser or PDT on the same site — Caution (theoretical): DMSO is already used to support PDT drug penetration in BCC (Christensen et al., 2009); stacking treatments risks excess inflammation. Mitigation: completing one treatment before starting another.

Populations who should avoid Topical Ascorbic Acid & DMSO:

  • People with infiltrative, morpheaform or recurrent BCC (NCT04279535 exclusion criteria)
  • BCC on the nose, ear, eyelid, eyebrow or temple (NCT04279535 exclusion criteria)
  • SCC larger than 2 cm or deeper than 2 mm (NCT05932511 exclusion criteria)
  • Immunocompromised people (NCT05932511 exclusion criteria)
  • Any lesion not confirmed by biopsy, including suspected melanoma (no data)
  • Pregnancy and breastfeeding: no adequate human studies exist; the Rimso-50 label limits use in pregnancy to cases where benefit justifies fetal risk and advises caution when nursing
  • Known hypersensitivity to DMSO: the Rimso-50 label warns of occasional hypersensitivity reactions with topical use
  • Children, in whom safety has not been established (Rimso-50 label)

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Biopsy before treatment: Both registered combination trials required biopsy-confirmed BCC or SCC (NCT04279535; NCT05932511); this prevents topical treatment of melanoma or aggressive subtypes that need surgery.
  • Biopsy after treatment: A repeat punch biopsy (small cylindrical skin sample) six weeks after the 8-week course (NCT04279535) detects residual tumor hidden beneath healed-looking skin, mitigating incomplete clearance.
  • Surgical backup booked in advance: The BCC trial scheduled Mohs surgery for every participant at enrollment (NCT04279535), so treatment failure caused no delay in definitive treatment.
  • Lesion-only application: The BCC trial brushed 0.2–0.3 mL onto the lesion with a small cuticle brush (NCT04279535), keeping solution off surrounding skin and limiting irritation, odor and systemic DMSO exposure.
  • Patch test: One drop on the inner forearm 24–48 hours before the first treatment screens for hives or DMSO hypersensitivity.
  • Stop rules: Blistering, ulceration, spreading hives, breathing difficulty, numbness or lesion growth are stopping points for medical review, since they signal hypersensitivity, nerve injury or treatment failure.
  • Pharmaceutical-grade ingredients: Pharmacopeia-grade DMSO and ascorbic acid avoid contaminants that DMSO would carry into skin (ConsumerLab).
  • Fresh, light-protected solution: Ascorbic acid degrades on contact with air and light (Pernice et al., 2021); small fresh batches in dark glass prevent under-treatment from a weakened solution.
  • No layering of other topicals: Keeping other creams off the treated site during the course prevents DMSO-driven absorption of steroids, antibiotics or irritants.

Therapeutic Protocol

Timing, cycling and titration details without a citation reflect common practice.

  • Combination regimen (Burke protocol): 30% (w/v, weight per volume) ascorbic acid in 95% DMSO plus 5% water, 0.2–0.3 mL brushed onto the lesion twice daily, every day (NCT04279535); developed by Briant Burke, Center for Biomedical Research, Boise.
  • Course length: 8 weeks for nodular or superficial BCC (Burke & Bailie, 2022), stopping earlier if the lesion clears (NCT04279535), and in the registered SCC pilot (NCT05932511); 12 weeks for SCC in situ (Miller et al., 2025).
  • Aqueous alternative (Budapest protocol): 33 g ascorbic acid per 100 mL water under a bandage for at least 12 hours daily over 22 weeks (Holló et al., 2016), as summarized by Pernice et al., 2021; no DMSO.
  • Supersaturated aqueous alternative (Reggio Emilia protocol): 40–70% ascorbic acid at pH 1.2–3.5, left on 4–12 hours daily for 30 days before limited surgery (Pernice et al., 2021); developed by Pier Cesare Capponi’s group.
  • Conventional options: Surgical excision or Mohs surgery shows the lowest recurrence; imiquimod 5% cream has the strongest support among non-surgical options (Thomson et al., 2020); in the comparison trial it was applied 5 days per week (NCT04279535).
  • Time of day: Morning and evening applications on clean, dry skin, letting the solution dry before clothing or bandage contact.
  • Half-life: Ascorbic acid’s skin half-life was about 4 days in pigs (Pinnell et al., 2001), unmeasured in humans; DMSO has no fixed half-life because elimination saturates (Egorin et al., 1998); its metabolite dimethyl sulfone persists over two weeks (Rimso-50 label).
  • Single versus split dosing: Split into two daily applications as in both combination studies; no once-daily comparison exists.
  • Genetic factors: No gene-based dosing data exist; people with G6PD deficiency face only theoretical hemolysis risk at lesion doses (Juneja et al., 2022).
  • Sex: Women and men received identical dosing in the trials; no sex-specific response or dose data exist.
  • Age: Studied in adults aged 18–80 (NCT04279535); older adults with limited dexterity or vision may need help applying the solution precisely.
  • Baseline biomarkers and lesion size: No blood marker guides dosing. Studied lesions averaged about 11–13 mm for BCC (NCT04279535); the SCC pilot excluded cancers larger than 2 cm or deeper than 2 mm (NCT05932511); larger lesions fall outside the evidence.
  • Pre-existing conditions: With eczema or thin skin around the lesion, petroleum jelly on surrounding skin is a common barrier; immunosuppression places SCC outside the studied population.

Discontinuation & Cycling

  • Short-term course: A fixed course of 8 weeks for BCC or 12 weeks for SCC in situ, not lifelong; both agents stop together because they are delivered in one solution.
  • Withdrawal effects: None known for either agent.
  • Tapering: Not required; application simply stops after the course or confirmed clearance.
  • Cycling: Not used to maintain efficacy; the BCC trial gave one fixed course, with Mohs surgery booked as backup rather than repeat cycles (NCT04279535).
  • After stopping: Garlic-like odor can persist up to 72 hours (Rimso-50 label); skin checks continue to detect recurrence or new lesions.

Sourcing and Quality

  • DMSO grade: Pharmaceutical-grade DMSO meeting United States Pharmacopeia standards only; industrial solvent grades may contain contaminants such as pesticides that DMSO carries through skin (ConsumerLab).
  • Ascorbic acid form: Pure L-ascorbic acid crystalline powder; derivatives such as magnesium ascorbyl phosphate or ascorbyl palmitate did not raise skin ascorbic acid levels (Pinnell et al., 2001).
  • Formulation: No commercial product exists; the trial solution was 30% w/v ascorbic acid in DMSO with 5% water (NCT04279535); the Italian solution was compounded under Good Manufacturing Practices (Pernice et al., 2021).
  • Compounding pharmacies: A prescribing physician and a licensed compounding pharmacy can prepare the solution with a certificate of analysis for each ingredient.
  • Storage: Dark glass bottles, cool storage and small batches; DMSO dissolves some plastics, and browning of the solution signals ascorbic acid oxidation.
  • Third-party testing: Certificates of analysis confirming identity, purity and absence of heavy metals for the powder and the solvent.

Practical Considerations

  • Time to effect: Biopsy-confirmed clearance of BCC was assessed at 8 weeks (Burke & Bailie, 2022), with an interim visit at 4 weeks to track early change (NCT04279535).
  • Common pitfalls: Treating lesions without a biopsy, stopping when the surface looks healed, skipping the post-treatment biopsy, using industrial DMSO, treating large areas, and layering other creams on the site.
  • Regulatory status: DMSO’s only approved human drug indication is bladder instillation for interstitial cystitis (Rimso-50 label); the ascorbic acid–DMSO solution is investigational and registered as a drug regulated by the FDA (US Food and Drug Administration) in its trial (NCT04279535).
  • Cost and accessibility: Ingredients are inexpensive, but biopsies before and after treatment still require a dermatologist; surgery costs considerably more.
  • Payer and professional incentives: Insurers and national health systems have a financial incentive to favor cheaper non-surgical treatment, while surgeons earn procedure fees; both incentives are potential sources of structural bias in guideline formation and research funding.
  • Sponsorship of comparator evidence: Commercial sponsors conducted most imiquimod trials and nearly half of PDT trials in the Cochrane review (Thomson et al., 2020), while the combination’s evidence comes from its developers’ own research company.

Interaction with Foundational Habits

  • Sleep: No direct interaction; neither agent is known to affect sleep. DMSO’s garlic-like odor can disturb a bed partner, so evening application may be shifted earlier in the evening to let odor fade.
  • Nutrition: No direct interaction. Oral vitamin C cannot reach the tissue concentrations of topical application (Padayatty et al., 2004), so dietary vitamin C neither adds to nor blunts the local effect; garlic-like odor is unrelated to diet.
  • Exercise: Indirect interaction: sweat can spread the solution onto surrounding skin, so applying after workouts and showering limits irritation. Outdoor exercise adds ultraviolet exposure, which drives new skin cancers; covering the treated site protects it.
  • Stress management: Indirect interaction: avoiding surgery may lower procedural anxiety, while uncertainty until the follow-up biopsy may raise it. Neither agent is known to affect cortisol or the stress response.

Monitoring Protocol & Defining Success

Baseline testing before starting centers on a diagnostic biopsy confirming nodular or superficial BCC, a measurement and photograph of the lesion, and, for people of African, Mediterranean, Middle Eastern or Asian ancestry, a G6PD activity test. A full skin examination checks for other suspicious lesions that need separate assessment. Because lens changes occurred in animals, the Rimso-50 label recommends a slit-lamp eye examination (microscope check of the lens) before and periodically during DMSO treatment.

Ongoing monitoring follows the trial schedule: review at 4 weeks and 8 weeks, a repeat biopsy about 6 weeks after the course ends, then skin checks every 6–12 months, mirroring the trial’s follow-up at 12, 24 and 30 months (NCT04279535). Success is defined as no carcinoma on the repeat biopsy, no recurrence at follow-up, and an acceptable cosmetic result.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Lesion biopsy histology No residual carcinoma on repeat biopsy (trial endpoint, Burke & Bailie 2022) Expected to change; defines success or failure Histology (microscopic tissue examination). Source: Burke & Bailie, 2022. Conventional reference: normal skin histology. Repeat punch biopsy about 6 weeks after the course ends.
Lesion size (longest diameters, area) No established target; track change from the individual’s own baseline Expected to change; tracks response Mean BCC diameter at entry was about 11–13 mm (NCT04279535). Measured and photographed at each visit under the same lighting.
G6PD activity About 9.6–16.3 U/g hemoglobin in adults, varying by laboratory (standard reference range) Safety check; deficiency changes use G6PD (glucose-6-phosphate dehydrogenase, a red-blood-cell enzyme); deficiency underlies most vitamin C hemolysis (Juneja et al., 2022). Once-only test; no fasting needed.
Liver and kidney panel with complete blood count ALT 7–56 U/L, creatinine 0.6–1.3 mg/dL, hemoglobin 12.0–17.5 g/dL, white cells 4.0–11.0 ×10⁹/L, platelets 150–450 ×10⁹/L (standard reference range) Safety check for repeated or prolonged DMSO courses ALT (alanine aminotransferase, a liver enzyme). The Rimso-50 label advises these tests about every six months during ongoing DMSO treatment; relevant only if courses are repeated.

Qualitative markers:

  • Degree of burning, itching or redness after each application
  • Garlic-like odor and its effect on daily life
  • Lesion appearance: crusting, bleeding, flattening, or new growth at the edges
  • Pigment and texture of the treated skin after healing
  • New suspicious spots elsewhere on the skin

Emerging Research

  • SCC pilot trial (NCT05932511): Single-group pilot without blinding of 30% ascorbic acid in DMSO for SCC, estimated 15 participants, earliest-stage human trial, primary endpoint tumor-free biopsy at 8 weeks. Completion date passed (December 2024); status unknown, no results posted. Positive results would broaden evidence to invasive SCC; null results would confine it to BCC.
  • Independent replication: All combination data come from one research group. A scoping review judged the evidence too limited for recommendations (Johnston et al., 2026); a randomized trial from an unaffiliated center is the key missing piece.
  • Isolating DMSO’s contribution: No study has compared ascorbic acid with and without DMSO. Aqueous solutions also cleared lesions in small series (Holló et al., 2016); a three-arm trial would show whether DMSO adds benefit or only odor and irritation.
  • Comparison with surgery: Surgery shows the lowest recurrence across established treatments (Thomson et al., 2020). Recurrence data at three to five years would show whether the combination approaches surgery or resembles other topical options.
  • Limits of ascorbate therapy: Intravenous ascorbate in locally advanced BCC produced stable disease in 3 of 4 patients and progression in one (Bánvölgyi et al., 2020); a different route, but a sign that ascorbate may not shrink larger tumors. Topical trials in larger lesions would test this.
  • Recruiting trials: No recruiting trial of topical ascorbic acid with DMSO for skin cancer was found on ClinicalTrials.gov as of October 2026.

Conclusion

Concentrated vitamin C dissolved in dimethyl sulfoxide, brushed onto a skin cancer twice daily for about two months, is a low-cost, non-surgical approach built on a plausible idea: at very high local concentrations vitamin C generates hydrogen peroxide that some cancer cells cannot neutralize, and the solvent carries it below the skin surface.

For health-focused adults who prefer to avoid scars or repeated surgery, the evidence is encouraging but thin. In one small controlled comparison, the two agents applied together cleared low-risk basal cell cancers more often than a standard prescription cream and left no pale patches; for squamous cell cancers, only an early report without a comparison group exists, covering the surface-confined stage. All of this comes from a single research group working through its own small research company, and no independent team has repeated the work. The research on surgery and standard creams has its own interests behind it, with many cream trials run by manufacturers, while insurers have a reason to favor cheaper options and surgeons earn fees from procedures.

The main risks are local stinging and redness, a garlic-like odor, and, most importantly, a cancer that only partly responds while looking healed. The approach therefore depends on biopsies before and after treatment, careful lesion selection and pharmaceutical-grade ingredients. As it stands, the combination is an experimental option with early promise and real uncertainty about long-term cure rates.

Top - Benefits - Risks - Protocol